Xspray Pharma AB (publ) financials
Xspray Pharma AB (publ)
549300NGRQCNZ3X4L157 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 0 | SEK 0 |
| Other income | SEK 2.1M | SEK 31.8M |
| Operating profit (EBIT) | -SEK 287.0M | -SEK 181.7M |
| Net finance income / (cost) | SEK 1.4M | SEK 2.0M |
| Finance costs | SEK 1.9M | SEK 675.0K |
| Profit before tax | -SEK 285.7M | -SEK 179.7M |
| Income tax expense | -SEK 151.0K | -SEK 17.0K |
| Profit for the year | -SEK 285.5M | -SEK 179.7M |
| Total comprehensive income | -SEK 285.3M | -SEK 179.9M |
| Per share | ||
| Basic EPS | SEK -8.62 | SEK -6.76 |
| Diluted EPS | SEK -8.62 | SEK -6.76 |
| Free cash flow / share | SEK -6.84 | SEK -7.74 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 222.4M | -SEK 203.3M |
| Net cash from investing activities | -SEK 42.1M | -SEK 65.9M |
| Purchase of PP&E (capex) | SEK 4.4M | SEK 2.7M |
| Net cash from financing activities | SEK 306.1M | SEK 315.6M |
| Proceeds from borrowings | SEK 96.0M | SEK 45.0M |
| Lease liability payments | SEK 4.9M | SEK 1.7M |
| Net change in cash | SEK 41.6M | SEK 46.4M |
| Balance sheet | ||
| Total assets | SEK 796.3M | SEK 765.3M |
| Non-current assets | SEK 561.3M | SEK 547.4M |
| Right-of-use assets | SEK 32.2M | SEK 37.6M |
| Intangible assets & goodwill | SEK 478.9M | SEK 436.8M |
| Current assets | SEK 235.1M | SEK 217.8M |
| Inventories | SEK 20.3M | SEK 43.8M |
| Trade & other receivables | SEK 4.0M | SEK 4.2M |
| Cash & equivalents | SEK 208.2M | SEK 166.3M |
| Total equity | SEK 623.1M | SEK 693.4M |
| — attributable to owners | SEK 623.1M | SEK 693.4M |
| Non-current liabilities | SEK 27.1M | SEK 31.9M |
| Lease liabilities (non-current) | SEK 27.1M | SEK 31.9M |
| Current liabilities | SEK 146.1M | SEK 39.9M |
| Lease liabilities (current) | SEK 5.1M | SEK 4.9M |
| Derived metrics | ||
| Free cash flow | -SEK 226.7M | -SEK 206.0M |
| Return on equity | -45.8% | -25.9% |
| Cash conversion ratio | 0.78× | 1.13× |
| Capex coverage | -50.77× | -75.51× |
| Other reported items | ||
| Additional Paidin Capital | SEK 1.43B | SEK 1.22B |
| Adjusted Weighted Average Shares | 33.1M | 26.6M |
| Adjustments For Decrease Increase In Inventories | -SEK 6.0M | -SEK 35.2M |
| Adjustments For Decrease Increase In Trade and Other Receivables | SEK 1.3M | -SEK 4.1M |
| Adjustments For Depreciation and Amortisation Expense | SEK 8.5M | SEK 9.2M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -SEK 22.8M | -SEK 5.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 9.3M | SEK 7.8M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -SEK 32.0K | SEK 41.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 227.0M | -SEK 171.7M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 18.6M | SEK 16.3M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | SEK 96.0M | SEK 0 |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 2.5M | SEK 3.6M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 334.0K | -SEK 306.0K |
| Equity and Liabilities | SEK 796.3M | SEK 765.3M |
| Finance Income | SEK 3.3M | SEK 2.7M |
| Increase Decrease Through Transactions With Owners | SEK 215.0M | SEK 317.2M |
| Intangible Assets Under Development | SEK 478.9M | SEK 436.8M |
| Interest Paid Classified As Operating Activities | SEK 2.9M | SEK 1.2M |
| Interest Received Classified As Operating Activities | SEK 2.2M | SEK 2.0M |
| Issue of Equity | SEK 235.4M | SEK 342.9M |
| Issued Capital | SEK 37.1M | SEK 31.3M |
| Noncurrent Financial Assets | SEK 3.2M | SEK 3.0M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | SEK 1.0K | SEK 1.0K |
| Other Comprehensive Income | SEK 205.0K | -SEK 184.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | SEK 205.0K | -SEK 184.0K |
| Other Current Payables | SEK 9.3M | SEK 6.3M |
| Other Expense By Function | SEK 5.9M | SEK 3.7M |
| Other Noncurrent Receivables | SEK 3.2M | SEK 3.0M |
| Other Reserves | SEK 997.0K | SEK 792.0K |
| Payments For Development Project Expenditure | SEK 37.8M | SEK 49.9M |
| Payments For Share Issue Costs | SEK 21.5M | SEK 26.2M |
| Proceeds From Issuing Shares | SEK 235.4M | SEK 297.9M |
| Research and Development Expense | SEK 79.4M | SEK 40.3M |
| Retained Earnings | -SEK 840.2M | -SEK 554.7M |
| Selling General and Administrative Expense | SEK 203.9M | SEK 169.6M |
| Share Issue Related Cost | SEK 21.5M | SEK 26.2M |
| Trade and Other Current Payables To Trade Suppliers | SEK 17.1M | SEK 12.5M |
| Weighted Average Shares | 33.1M | 26.6M |
Every line item above is a fact tagged in Xspray Pharma AB (publ)'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.